🇺🇸 FDA

Drug profile · INN

chlorotrianisene

TACE

approved
US status
approved
Patents linked
6
News articles
0

Quick answer

chlorotrianisene (TACE) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN chlorotrianisene
Brand TACE
Route ORAL
Formulation CAPSULE

Related patents

Search patents →

  1. US 9346866

    Inhibition of tace activity with cyclic peptides

    Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8168588

    Compositions comprising FGF-9 and betacellulin and methods for treating cardiac conditions

    Expires Mon Apr 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 7919520

    Inhibitors of tace

    Expires Mon Mar 31 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 7485664

    Inhibitors of TACE

    Expires Mon Jan 29 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 6825165

    Betacellulin modification

    Expires Mon Nov 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  6. US 6183971

    Human betacellulin-specific antibodies and uses thereof

    Expires Mon Feb 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is chlorotrianisene?

chlorotrianisene (TACE) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for chlorotrianisene?

TACE is a marketed brand name for chlorotrianisene. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of chlorotrianisene?

chlorotrianisene has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.